Cash generation reached an inflection point in 2025Q3 with $23.3 million in operating cash flow and a 30.0% free cash flow margin, marking a departure from previous periods of heavy cash burn.
| Metric | TTM | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 35.6M | -46.91M | -128.51M | -70.3M | -77.31M | -48.73M | -38.33M | -82.72M | 16.66M | 18.9M | 84.29M | -10.62M | -20.68M | -23.14M | -10.32M | -5.46M | 8.2M | -7.51M | -19.24M | -29.83M | -19.39M | -4.15M | 12.23M | 8.77M | -2.78M | -5.62M | -4.24M | -8.19M | -8.9M | -4.2M |
| Operating CF Margin % | - | -27.74% | -459.58% | - | - | -218.21% | -64.72% | -80.1% | 9.65% | 12.58% | 48.67% | -71.86% | -92.13% | -88.65% | -31.67% | -14.71% | 19.46% | -19.44% | -52.49% | -129.57% | -82.16% | -7.49% | 48.58% | 47.65% | -21.27% | -51.57% | -38.4% | -85.99% | -109.88% | -85.71% |
| Operating CF Growth % | 807.78% | 63.5% | -82.79% | 9.06% | -58.64% | -27.16% | 53.67% | -596.43% | -11.85% | -77.58% | 893.87% | 48.65% | 10.64% | -124.15% | -89.17% | -166.59% | 209.15% | 60.98% | 35.49% | -53.83% | -367.2% | -133.94% | 39.4% | 415.05% | 50.48% | -32.63% | 48.23% | 8% | -111.9% | - |
| Net Income | -278K | -48.83M | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.3M | 67.25M | -41.28M | 40.66M | -84.91M | -42.92M | -3.23M | -8.77M | -8.97M | -11.44M | -12.08M | -37.74M | -35.2M | -27.38M | 12.5M | -3.49M | 3M | -2.87M | -9.46M | -6.69M | -7.81M | -6.8M | -6.9M |
| Depreciation & Amortization | 3.68M | 2.68M | 1.77M | 1.49M | 815K | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.7M | 5.92M | 7.25M | 6.2M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700K | 900K |
| Stock-Based Compensation | 13.64M | 20.39M | 15.81M | 7.01M | 8.87M | 3M | 519K | 7.85M | 8.07M | 14.68M | 7.74M | 2.69M | 2.03M | 3.04M | 2.78M | 3.17M | 5.5M | 8.29M | 9.99M | 546K | 1.39M | 1.39M | 23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 26.02M | -15.67M | -7.43M | -6.33M | -19.15M | 3.56M | -4M | 1.42M | -2.81M | -11.32M | -4.76M | 5.5M | -4.2M | -8.17M | -9.97M | -11.24M | -2.16M | -5.13M | -1.39M | -23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 25.4M | -828K | 17.19M | 8.09M | 2.3M | -44.88M | -4.02M | 28.17M | -69.53M | 33.7M | 26.15M | 52.03M | 30.18M | -12.68M | -8.77M | 3.17M | 5.5M | 8.29M | 11.69M | 10M | 546K | 967K | -575K | 18K | 23K | 20K | 74K | 95K | 200K | -11.1M |
| Working Capital Changes | -6.83M | -20.32M | -3M | 24.54M | 3.69M | -8.13M | 2.25M | -11.71M | 2.42M | 1.31M | -4.81M | 8.23M | -1.7M | -8.69M | -4.39M | -3.32M | 10.89M | -9.27M | 1.87M | -8.66M | 6.44M | -20.15M | 14.58M | 4.29M | -1.2M | 2.71M | 1.17M | -1.51M | -3M | 12.9M |
| Change in Receivables | -5.47M | -21.99M | -10.22M | 30K | 2.8M | 10.49M | 1.46M | 3.45M | 3.08M | -10.05M | -8.11M | 3.43M | -512K | 2.61M | -464K | 733K | -1.26M | -2.39M | 15K | 4.77M | 216K | 216K | -5.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -8.06M | -9.22M | -9.53M | -30K | 0 | -1.35M | 1.16M | 711K | -2.9M | 1.83M | 2.55M | -3.11M | -2.19M | 176K | -917K | 152K | 909K | -171K | 1.82M | -2.06M | 351K | -419K | -569K | 271K | 251K | -682K | 536K | -653K | 100K | -100K |
| Change in Payables | 4.62M | -4.09M | 1.54M | -3.11M | 4.23M | -2.79M | 4.64M | -2.03M | 596K | -434K | -3.89M | 1.09M | 1.32M | -613K | -825K | -450K | 32K | -258K | -2.99M | 3.3M | 4.49M | 4.49M | -259K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 10.19M | 51.78M | -50.09M | 79.7M | 56.93M | -69.72M | 38.72M | -36.98M | -15.7M | -36.63M | -31.73M | -43.08M | 6.04M | 15.45M | -351K | 6.03M | -24.26M | 911K | -13.23M | 72.67M | -4.5M | 2.08M | -1.92M | -1.43M | -1.18M | -737K | 3.39M | 1.41M | -1.6M | -9.3M |
| Capital Expenditures | -191.76K | 0 | 0 | -716K | -26K | -98K | -29K | -20.18M | -53.7M | -1.2M | -1.63M | -1.73M | -1.03M | -1.07M | -1.9M | -3.6M | -1.77M | -3.52M | -11.27M | -6.39M | -11.33M | -13.84M | -2.84M | -1.44M | -1.18M | -737K | -673K | -1.13M | -1.6M | -1.5M |
| CapEx % of Revenue | 0.08% | - | - | - | - | 0.44% | 0.05% | 19.54% | 31.09% | 0.8% | 0.94% | 11.7% | 4.58% | 4.1% | 5.84% | 9.7% | 4.2% | 9.12% | 30.75% | 27.78% | 48% | 24.97% | 11.29% | 7.8% | 9% | 6.76% | 6.1% | 11.88% | 19.75% | 30.61% |
| Acquisitions | 0 | 0 | 0 | -80.41M | 16.5M | 25.5M | 0 | 20M | 53.11M | 628K | 779K | 0 | 0 | 1.77M | 0 | 0 | -327K | -327K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -15.69M | 0 | 0 | 80.41M | 0 | 0 | 154K | -20M | -53.11M | -36.06M | -779K | 13.24M | 1.01M | 67K | 185K | 131K | 327K | 327K | 47K | 92K | 154K | 543K | 918K | 3K | 3K | 0 | 4.07M | 6.78M | 0 | -7.8M |
| Cash from Financing | 5.19M | 15.97M | 135.34M | 14.54M | 263K | 179.68M | -27K | 112.66M | -23.32M | -7.95M | -23.75M | 96M | 18.27M | 6.96M | 6.14M | -774K | -1.58M | 8.88M | 3.02M | 5.48M | 21.08M | 5.09M | 74.43M | 402K | -196K | 11.62M | -40K | 9.85M | 600K | 27.9M |
| Debt Issued (Net) | 0 | 0 | -38.66M | 0 | 0 | 0 | 0 | 143.75M | 0 | 0 | -4.91M | -34.35M | 19.26M | 6.35M | 5.85M | -1.48M | 2.12M | 8.34M | 398K | -72K | 3.07M | 444K | -55K | 401K | -196K | -107K | -40K | -345K | 0 | -700K |
| Equity Issued (Net) | 2.69M | 1000K | 1000K | 1000K | 0 | 1000K | 118K | -1000K | -1000K | 440K | 1000K | 1000K | 400K | 607K | 296K | 704K | 291K | 540K | 569K | 1000K | 1000K | 764K | 1000K | 1K | 0 | 1000K | 0 | 1000K | 700K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -27.64M | -22.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 815.49K | 6.72M | 27.94M | -10.78M | 263K | 0 | -145K | -4.03M | -1.36M | -8.39M | -25.83M | -1.92M | -1.38M | 0 | 0 | 0 | -4M | 0 | 2.06M | 2.94M | 4.36M | 3.88M | -997K | 0 | 0 | 0 | 0 | 0 | -100K | 100K |
| Net Change in Cash | 51.23M | 20.2M | -42.81M | 23.27M | -21.01M | 61.95M | 449K | -7.24M | -22.65M | -25.85M | 25.3M | 33.12M | 3.89M | -714K | -4.73M | -532K | -18.3M | 708K | -25.52M | 50.81M | -3.57M | 3.39M | 95.09M | 9.22M | -4.83M | 4.93M | -2.07M | 3.47M | -11.7M | 14.5M |
| Free Cash Flow | 35.41M | -46.91M | -128.51M | -71.02M | -77.34M | -48.83M | -38.35M | -102.89M | -37.04M | 17.7M | 82.66M | -12.35M | -21.7M | -24.21M | -12.23M | -9.06M | 6.42M | -11.03M | -30.51M | -36.22M | -30.71M | -17.99M | 9.39M | 7.34M | -3.96M | -6.36M | -4.91M | -9.32M | -10.5M | -5.7M |
| FCF Margin % | 14.25% | -27.74% | -459.58% | - | - | -218.64% | -64.77% | -99.64% | -21.44% | 11.78% | 47.73% | -83.56% | -96.71% | -92.75% | -37.5% | -24.41% | 15.25% | -28.56% | -83.25% | -157.34% | -130.16% | -32.46% | 37.29% | 39.86% | -30.27% | -58.33% | -44.49% | -97.87% | -129.63% | -116.33% |
| FCF Growth % | 142.76% | 63.5% | -80.95% | 8.17% | -58.37% | -27.32% | 62.72% | -177.79% | -309.27% | -78.59% | 769.56% | 43.12% | 10.34% | -98% | -35% | -240.95% | 158.24% | 63.85% | 15.76% | -17.92% | -70.76% | -291.64% | 27.94% | 285.16% | 37.69% | -29.46% | 47.29% | 11.25% | -84.21% | - |
| FCF per Share | 0.35 | -0.49 | -1.60 | -1.18 | -1.32 | -0.89 | -1.03 | -2.76 | -0.89 | 0.43 | 1.90 | -0.34 | -0.85 | -0.97 | -0.50 | -0.37 | 0.27 | -0.46 | -1.27 | -1.52 | -1.34 | -0.76 | 0.53 | 0.44 | -0.24 | -0.41 | -0.38 | -0.77 | -1.00 | -0.66 |
| FCF Conversion (FCF/Net Income) | -127.36x | 0.96x | 0.80x | 0.51x | 1.00x | -6.93x | 1.15x | 0.87x | 0.25x | -0.46x | 2.07x | 0.13x | 0.48x | 7.17x | 1.18x | 0.61x | -0.72x | 0.62x | 0.51x | 0.85x | 0.71x | -0.33x | -3.50x | 2.92x | 0.97x | 0.59x | 0.63x | 1.05x | 1.31x | 0.61x |
| Interest Paid | 5.84M | 0 | 0 | 0 | 6.47M | 6.47M | 6.47M | 3.36M | 1.05M | 788K | 4.74M | 4.43M | 1.7M | 118K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 76K | 0 | 140K | 776K | 19.14M | 27.18M | 42.12M | 403K | 153K | 56K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Single product concentration risk
According to recent financial disclosures, AVDL's operating cash flow reached $23.3 million in 2025Q3, representing a significant inflection point where cash generation has finally decoupled from the persistent net losses that characterized the company's earlier commercial launch phase and heavy investment in market access infrastructure.
The dramatic shift in the OCF/NI ratio suggests that the company is successfully managing its working capital as it scales. Investors should monitor whether this conversion quality remains sustainable as the company moves past the initial launch-related cash burn and into a more mature phase of revenue realization.
As reported in quarterly filings, AVDL achieved a positive free cash flow margin of 30.0% in 2025Q3, marking a decisive transition from the cash-burning trajectory observed throughout 2023 and early 2024, when the company was heavily reliant on capital deployment to fund its commercial launch.
This trajectory indicates that the underlying economics of the LUMRYZ launch are beginning to yield meaningful cash returns. The rapid improvement in FCF margins suggests that the fixed-cost nature of the company's specialty sales force is now being effectively leveraged against a growing revenue base.
Based on the provided cash flow statements, AVDL experienced a working capital outflow of $3.8 million in 2025Q3, which appears to be a natural byproduct of the company's rapid revenue expansion and the associated increase in accounts receivable as the patient base grows.
The volatility in working capital changes over the last ten quarters reflects the complexities of managing a specialty pharmacy distribution model. Analysts should investigate whether these outflows are indicative of longer collection cycles or simply a temporary mismatch between shipment timing and cash receipt.
As highlighted in recent financial statements, AVDL's cash flow statement reveals a consistent reliance on stock-based compensation, which averaged over $4 million per quarter during the launch phase, effectively masking the true cash cost of talent acquisition and retention during this critical growth period.
While SBC is a non-cash expense, it represents a real economic cost to shareholders that is not fully captured in the operating cash flow figures. Investors should consider the dilutive impact of these equity grants when evaluating the long-term sustainability of the company's current cash flow generation.
Quick answers to the most common questions about buying AVDL stock.
Avadel Pharmaceuticals plc (AVDL) generated $-46.9M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Avadel Pharmaceuticals plc (AVDL) reported negative free cash flow of $46.9M in 2024, indicating capital requirements exceeded cash from operations.
Avadel Pharmaceuticals plc (AVDL) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.